Major Organs and Cancer —
Training activity: 10

Details

Perform the fluid analyses involved in the detection of major organ disease and cancers to laboratory standard operating procedures to include:

• Pleural fluid chylothorax
• Pleural fluid transudates vs exudates
• Ascitic fluid

 

 

Type

Entrustable training activity (ETA)

Evidence requirements

Evidence the activity has been undertaken by the trainee repeatedly, consistently, and effectively over time, in a range of situations. This may include occasions where the trainee has not successfully achieved the outcome of the activity themselves. For example, because it was not appropriate to undertake the task in the circumstances or the trainees recognised their own limitations and sought help or advice to ensure the activity reached an appropriate conclusion. ​

Reflection at multiple timepoints on the trainee learning journey for this activity.

Reflective practice guidance

The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.

Before action

What does success look like?

• What is expected of you in relation to effectively performing and interpreting analyses on these less common bodily fluids (e.g., pleural and ascitic fluid) according to your laboratory Standard Operating Procedures (SOPs)?
• How will you apply the specific learning outcomes for this module, particularly regarding performing biochemical assays, analysing and interpreting the resultant data, and evaluating national guidelines for major organ disease and cancer?
• Have you discussed with your training officer to gain clarity on the expected levels of analytical accuracy, precision, and the specific requirements for identifying chylomicrons or assessing transudates versus exudates?

What is your prior experience of this activity?

• What do you already know about the unique properties of bodily fluids (such as viscosity or cellularity) compared to standard blood and urine samples, and how these factors affect laboratory analysis?
• What challenges do you anticipate facing, such as managing limited sample volumes that necessitate test prioritisation, or dealing with highly turbid samples when investigating suspected chylothorax?
• How well do you recognise the scope of your own practice for this activity; do you know exactly when and to whom you should seek advice, such as when a sample exhibits unusual physical characteristics or suggests a rare malignancy?
• How do you feel about embarking on the analysis of these specialised, non-routine sample types that are often critical in acute clinical presentations?

What do you anticipate you will learn from the experience?

• What specific analytical skills do you want to develop, such as adapting standard techniques to handle diverse fluid matrices?
• What insights do you hope to gain regarding the clinical significance of these analyses in the context of major organ diseases (e.g., cardiac or renal) and how they support patient diagnosis and monitoring?
• How will this experience help you understand the relationship between the biochemical markers (such as protein and LDH for Light’s criteria) and the underlying pathophysiology of effusions and ascites?

What additional considerations do you need to make?

• Have you consulted actions or improvements identified from your previous experiences with fluid analysis or other complex automated/manual biochemical assays?
• What critical information must you consider before starting, such as patient clinical history, specific pre-analytical requirements for each fluid type, and the necessary safety and infection control protocols for potentially biohazardous samples?
• Have you ensured you have full access to the specific SOPs for each fluid type and have reviewed the national guidelines relevant to the management of these conditions?

In action

During the activity did anything unexpected occur?

• Are you noticing anything surprising or different from what you anticipated whilst performing the biochemical assays on these non-routine fluid types?
• Are you encountering technical situations such as:
  • The viscosity or cellularity of the pleural or ascitic sample compromising instrument aspiration or the accuracy of the analytical method?
  • A limited sample volume that restricts the range of required tests (e.g., protein, LDH, or triglycerides), necessitating an immediate decision on test prioritisation?
  • An unusual physical appearance, such as high turbidity or a milky appearance in a pleural sample, that suggests the presence of chylomicrons and may require a specialised analytical technique or alternative testing strategy?
• How does this experience compare with previous fluid analyses you have performed, particularly regarding the differentiation of transudates and exudates using established biochemical criteria?

How did you react to the unexpected development?

• How is the unexpected development impacting your actions; for example, are you adapting your approach to sample pre-treatment (such as centrifugation or dilution) to handle a viscous specimen appropriately?
• Consider the steps you are taking in the moment to ensure analytical quality, such as:
  • Immediately consulting the Standard Operating Procedure (SOP) to troubleshoot a technical flag or analyser error code related to the fluid matrix.
  • Halting the analysis to seek immediate guidance from a lead scientist or duty biochemist to determine the most clinical relevant tests to prioritise for a low-volume ascitic sample.
  • Cross-referencing the national guidelines (e.g., Light’s criteria) to ensure the correct analytes are being measured to distinguish between a transudate and an exudate.
• How are you feeling in that moment? For instance, are you finding it difficult to adapt a standard automated assay to a specialised fluid matrix, and is this affecting your confidence in assessing the sample’s suitability for analysis?

What was the conclusion or outcome?

• How are you identifying whether you are working within your scope of practice? For example, are you successfully applying technical adaptations to analyse the fluid according to the SOP, or do you need support because the sample suggests a rare malignancy or a highly unusual pathological presentation?
• What are you learning as a result of the unexpected development; for instance, are you mastering a more effective technique for verifying sample integrity in milky or turbid fluids?
• How has this real-time adjustment improved your insight into the clinical significance of markers like cholesterol and triglycerides or LDH in diagnosing major organ disease and cancer?

On action

What happened?

• You should begin by summarising the key steps you took when performing these specialised fluid analyses, such as assessing pleural fluid for triglycerides to confirm a chylothorax or measuring protein and LDH to differentiate transudates from exudates.
• Consider any specific actions that felt important, such as the systematic process you followed to manage viscous or turbid samples and how you applied the patient’s clinical history to your analytical approach.
• Include any ‘reflect-in-action’ moments where you had to adapt, such as halting the analysis to prioritise tests due to limited sample volume or consulting a senior colleague when a sample’s appearance was highly unusual.
• Reflect on your feelings during the experience, such as whether you felt confident in applying laboratory SOPs for these non-routine matrices or stressed by the complexity of managing time-critical samples for acute clinical scenarios.

How has this experience contributed to your developing practice?

• Identify what you have learned regarding the performance of biochemical assays on specialised fluids and how you demonstrated strengths, such as meticulous adherence to SOPs for unusual sample matrices.
• Evaluate any knowledge gaps that became evident, such as unfamiliarity with specific interpretation criteria for ascitic markers or the nuances of Light’s criteria for pleural effusions.
• Compare this experience to your prior engagement with routine blood or urine analyses; assess if your practice has improved in understanding the relationship between fluid biochemistry and major organ pathophysiology.
• Identify any significant challenges you faced, such as the need to seek advice or escalate a case to ensure you were working within your scope of practice, particularly if a result suggested a rare malignancy or complex co-morbidity.
• Acknowledge any changes in your feelings now that you are looking back; for instance, do you feel more determined to master the technical challenges of esoteric fluid analysis?

What will you take from the experience moving forward?

• Identify the ‘next steps’ you will take to support the assimilation of your learning, such as reviewing national guidelines for the management of pleural effusions or ascites to ensure your future advice is context-appropriate.
• Consider what you will do differently next time, such as proactively checking the sample’s physical characteristics (e.g., colour, turbidity) against the SOP’s expected matrix before commencing the run.
• Determine if you need to practise any aspect of the activity further, such as refining your technique for troubleshooting instrument flags caused by fluid viscosity or improving your clinical reporting for complex fluid patterns.
• Reflect on how this experience will help you in preparing for assessments like Case-Based Discussions (CBDs), where you may need to confidently discuss the investigation and interpretation of less common bodily fluids.

Beyond action

Have you revisited the experiences?

• How have your subsequent experiences of handling potentially biohazardous or complex non-routine samples since completing this specific training activity led you to revisit your initial approach or decisions during that activity? For example, how a subsequent case involving the differentiation of a pleural exudate from a transudate forced you to re-evaluate the meticulousness of the pre-analytical assessment and clinical history review you applied during your first attempt at this activity?
• Considering what you understand about sample matrix effects, specialised test requirements, and the diagnostic utility of esoteric fluid analysis now, were the actions or considerations you identified after your initial reflection on this training activity sufficient? How have you since implemented or adapted improvements in your handling and analytical adaptation for non-routine fluid types based on further learning and experiences? For example, how you proactively reviewed and integrated specific analytical techniques for assessing chylomicrons/triglycerides in turbid pleural samples to confirm chylothorax, demonstrating adaptability in specialised procedures?
• Has discussing analytical challenges with specific fluid types (e.g., viscosity or cell content) or their clinical significance with colleagues, peers, or supervisors changed how you now view your initial experience in this training activity? For example, how professional storytelling with a senior colleague about a case where a sample was rejected due to incorrect collection or missing protein/LDH measurements for Light’s criteria refined your understanding of the critical role of pre-analytical communication?

How have these experiences impacted upon current practice?

• How has the learning from this initial training activity, in combination with subsequent specialised fluid analysis experiences, contributed to your overall confidence and ability in handling diverse and complex sample matrices, particularly in preparing for assessments like Direct Observations of Practical Skills (DOPS) or Case-Based Discussions (CBDs)? For example, how your accumulated ability in performing biochemical assays on pleural and ascitic fluid and managing unusual sample matrices now enables you to confidently discuss the investigation of less common bodily fluids during a CBD assessment?
• How has reflecting back on this specific training activity, combined with everything you’ve learned since, shaped your current approach to handling and analysing non-routine fluid samples? How does this evolved understanding help you identify when something is beyond your scope of practice or requires escalation? For example, how your evolved approach means you now routinely seek advice from the lead scientist or duty biochemist immediately when an ascitic fluid sample presents a high biohazard risk or suggests a highly unusual pathological presentation/rare malignancy, recognising this requires senior judgment on patient safety and diagnostic yield?
• Looking holistically at your training journey, how has this initial fluid analysis experience, revisited with your current perspective, contributed to your development in meeting the learning outcomes related to evaluating national guidelines for the diagnosis and management of diseases associated with major organ systems? For example, how this foundational experience has supported your development in applying national criteria (such as Light’s criteria or guidelines for ascitic fluid analysis) to ensure accurate patient management and clinical advice?

Relevant learning outcomes

#	Outcome
# 1	Outcome Perform biochemical assays involved in the assessment of major organ function and cancer diagnosis and monitoring.
# 2	Outcome Analyse and interpret biochemical data generated in the assessment of major organ function and cancer diagnosis and monitoring.
# 3	Outcome Evaluate the national guidelines for diagnosis and management of diseases associated with the major organ systems and cancer.